Who
Karen J. Wilson
Director
Company insider
Files Form 4 as: Director, Elicio Therapeutics; Director, Serina Therapeutics; Director, LAVA Therapeutics NV; Director, Vaxart; SVP, Finance & PAO, Jazz Pharmaceuticals; VP of Finance & PAO, Pdl Biopharma.
In numbers
- Trades disclosed
- 131
- Buys
- 4
- Sells
- 18
- Bought
- $110K
- Sold
- $11.5M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 7 May 2009
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,8505,000 at $1.77 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,8505,000 at $1.77 | filing |
| 11 Jun 2026filed 15 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,9005,100 at $1.75 | filing |
| 11 Jun 2026filed 15 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,9255,100 at $1.75 | filing |
| 22 May 2026filed 26 May 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K10,000 at $1.93 | filing |
| 22 May 2026filed 26 May 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K10,000 at $1.93 | filing |
| 21 May 2026filed 26 May 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.77 | filing |
| 21 May 2026filed 26 May 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.77 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code D | —33,390 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NV | SEC FORM 4 Code D | —10,000 | filing |
| 7 Nov 2025filed 10 Nov 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 May 2025filed 20 May 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,900 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code A | —33,390 at $0.00 | filing |
| 14 Jan 2025filed 15 Jan 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
News
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Stock Short Interest Report for SeptemberSER · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Karen J. Wilson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.